Daily non-political popular news in brief.

Researchers shed light on mechanism of action used by anti-cancer drug

Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new mechanism of action of the anti-cancer drug sorafenib, which could stimulate the development of novel regimens in which it is combined with other molecularly targeted agents for patients with blood cancers and solid tumors.

Read more »

Keywords: researchers, shed, light, mechanism, action, used, anti-cancer, drug, researcher, anti, cancer

« Previous | Next »

Similar news on "Researchers shed light on mechanism of action used by anti-cancer drug":

1. Gold nanorods shed light on new approach to fighting cancer
   10-16-2007 · EurekAlert!
   Researchers have shown how tiny 'nanorods' of gold can be triggered by a laser beam to blast holes in the membranes of tumor cells, setting in motion a complex biochemical mechanism that leads to a tumor cell's self-destruction.
   Similar news · Read more »
   
2. Enzyme discovery sheds light on vitamin D
   07-24-2007 · EurekAlert!
   Surprising findings by Queen's University researchers have shed new light on how the "sunshine vitamin" D -- increasingly used to treat and prevent cancer and other diseases -- is broken down by our bodies.
   Similar news · Read more »
   
3. Modifying an anti-cancer drug makes it more specific
   12-03-2007 · EurekAlert!
   Imatinib is used to treat chronic myeloid leukemia and gastrointestinal stromal tumors because they are caused by related proteins. However, this lack of specificity means imatinib also affects normal bodily functions and it has been reported to have a toxic effect on the heart in some patients. Now, researchers have modified imatinib so it inhibits the protein behind GISTs but neither inhibits the protein behind CML nor has toxic effects on the mouse heart.
   Similar news · Read more »
   
4. Leukemia drug turns mini-molecules up, cancer genes down
   03-01-2007 · EurekAlert!
   New research shows that a form of vitamin A used to treat acute promyelocytic leukemia induces changes in an unusual class of small molecules called microRNAs (miRNAs) in the leukemic cells. The study also shows that three of these miRNAs inhibit the action of two genes important for cancer development, helping to explain how the drug works.
   Similar news · Read more »
   
5. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
   06-03-2007 · EurekAlert!
   North Central Cancer Treatment Group researchers based at Mayo Clinic in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.
   Similar news · Read more »
   
6. Support for chromosomal theory of cancer found in cancers' development of drug resistance
   06-27-2007 · EurekAlert!
   Most cancer researchers are convinced that cancer results from a handful of genetic mutations that kick a cell into uncontrolled growth. UC Berkeley genetics researcher Peter Duesberg disagrees, and finds support for his "chromosomal" theory of cancer in the development of drug resistance by many cancers. While his theory implies their is no magic bullet against cancer, it does provide ways to detect cancer at an early stage.
   Similar news · Read more »
   
7. Src inhibitors may prove beneficial in breast cancer therapy
   07-12-2007 · EurekAlert!
   Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development. However, one-third of new breast cancers lack detectable ER-alpha. These ER-alpha-negative cancers are more aggressive and have a worse prognosis than do ER-alpha-positive breast cancers, and have been thought to be estrogen independent. In a new JCI study, University of Miami researchers shed further light on the mechanisms regulating ER-alpha expression levels during breast cancer.
   Similar news · Read more »
   
8. Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
   02-10-2008 · EurekAlert!
   A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin.
   Similar news · Read more »
   
9. Jefferson scientists find guardian gene's choices crucial to stopping cancer process
   01-05-2007 · EurekAlert!
   Scientists at the Kimmel Cancer Center at Thomas JeffersonUniversity have uncovered a novel pathway by which the anti-cancer gene p53 springs into action, protecting a damaged cell from becoming cancer. The gene can either halt the cell's growth or send it spiraling toward certain death. How this choice is made, the researchers say, could have implications for future strategies in chemotherapy drug development.
   Similar news · Read more »
   
10. Researchers identify new drug targets for cancer
    12-28-2006 · EurekAlert!
    Solving a 100-year-old genetic puzzle, researchers at the UCSD School of Medicine have determined that the same genetic mechanism that drives tumor growth can also act as a tumor suppressor. Their findings could lead to new drug targets for cancer therapies.
    Similar news · Read more »